Phelix Research And Development
Phelix
- Country
- England & Wales
- Charity number
- 1156666
- Status
- Registered
- Reporting
- Up to date Last filed Oct. 31, 2025. Filing history
- Registered
- April 14, 2014
- Legal form
- Charitable company
- Company number
- 08820009
Address
- Address
- 37 Langton Street
London
SW10 0JL
Contact
- Phone
- 020 7352 4597
- contact@phelix.org.uk
- Website
Activities
THE MAIN OBJECTIVE IS TO RESEARCH THE NATURE, CASES, DIAGNOSES, PREVENTION, TREATMENT AND CURE OF INFECTIOUS DISEASES CAUSING THE MAIN NEURO DEGENERATIVE CONDITIONS. THE CHARITY CURRENTLY SUPPORTS RESEARCH ON BACTERIOPHAGES FOR CHRONIC INFECTIONS. IT INCLUDES THE RESEARCH AND DEVELOPMENT OF DIAGNOSTIC TESTS, PREVENTION TREATMENTS AND ULTIMATELY, THE CURE OF ANTIBIOTIC RESISTANT INFECTIOUS DISEASES
Objects: To Protect And Promote The Health Of The Public In Particular By Research Into The Nature, Cases, Diagnosis, Prevention, Treatment And Cure Of Chronic Infection Diseases, Including The Development Of Findings Of Research Into Practical Applications For The Prevention Treatment And Cure Of Chronic Infection Diseases And In Furtherance Of That Primary Objective, To Provide Information And Raise Public Understanding Of Such Matters; And To Support The Research On Bacteriophages For Bacterial Infections In A Chronic Phase And To Develop Therapeutic Programs Based On Bacteriophages.
Classification
- How
- Sponsors Or Undertakes Research
- What
- The Advancement Of Health Or Saving Of Lives
- Who
- The General Public/mankind
Geography
- Local Authority
- Kensington And Chelsea
Finances
| Period end | Filed | Income | Expenditure |
|---|---|---|---|
| Dec. 31, 2024 | Oct. 31, 2025On time | £47,314 | £78,663 |
| Dec. 31, 2023 | Jan. 17, 202578 days late | £38,570 | £41,229 |
| Dec. 31, 2022 | Oct. 14, 2024349 days late | £60,205 | £80,501 |
| Dec. 31, 2021 | Oct. 14, 2024714 days late | £95,193 | £95,918 |
| Dec. 31, 2020 | May 23, 2022204 days late | £96,064 | £114,043 |
Trustees
| Name | Appointed |
|---|---|
| Dr Louis Charles Teulieres | March 20, 2014 |
| Francois-Xavier Louvet | March 20, 2014 |